Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
eWWvMu3B0efv74ze
Listen
